All studies
Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional
A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Merck Sharp & Dohme LLC
Enrolment target
114
Start
11 Nov 2022
What is this study about?
Progression-free Survival (PFS), Overall Survival (OS)
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (6)
- —Sweden
- —Czechia
- —Poland
- —France
- —Germany
- —Italy
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.